Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for OPORF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for OPORF and 80,000+ other tickers.
See exactly how OPORF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OPORF and 80,000+ other tickers.
hVIVO plc functions as a contract research organization and pharmaceutical service provider, primarily dedicated to evaluating vaccines and antiviral medications. This is achieved through specialized human challenge clinical trials. The company extends its services to a varied clientele, encompassing major pharmaceutical and biotechnology firms, governmental bodies, and public health agencies. A significant aspect of its operations is a comprehensive array of human challenge study models. These cover conditions such as respiratory syncytial virus (RSV), influenza, human rhinovirus, asthma…
hVIVO PLC (AIM:HVO), the clinical trials group, has bought a Berlin clinical research unit for an initial payment of just €250,000, with almost all of the price contingent on future revenue. The company said on Thursday it had acquired the entire share capital of CRS Clinical Research Services Berlin, a specialist site running early-stage studies in dermatology and women's Instead of a fixed price, hVIVO will pay 18% of the Berlin unit's annual revenue for each of the next three years, provided minimum revenue thresholds are met.
This week hVIVO PLC (AIM:HVO) chief executive Mo Khan joined Proactive to talk about how the clinical research company has more than doubled its order book as commercial momentum accelerates. Khan said the company has transformed into an integrated end-to-end clinical development provider, with growing demand reflected in a 45% year-on-year increase in inbound client proposals.
The reveal that hVIVO Plc's (AIM:HVO) order book has more than doubled to £65 million, prompting Shore Capital to reiterate a Buy rating and 25p target price despite a steep second-half delivery challenge. The target implies 270% upside from the current 6.8p share price.
hVIVO PLC (AIM:HVO), the clinical trials specialist and world leader in human challenge studies, said its order book had more than doubled to £65 million since the start of the year. That compares with £30 million at the beginning of 2026 and gives the company far greater visibility over contracted revenues into 2027 and 2028.
hVIVO PLC's (AIM:HVO) consultancy contract with Decoy Therapeutics, announced on Monday, is a small deal by any financial measure, but Peel Hunt's reading of it points to something more strategically significant for the AIM-listed contract research organisation. The agreement covers a wide range of services to support Decoy's development of its Designable Multi-Antiviral candidates, a novel antiviral category targeting shared mechanisms across multiple respiratory viruses with a single, adaptable therapeutic approach.